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Leukocyte immunotherapies have made a great progress
and hold much promise in the treatment of cancer.
Specifically, in the case of B cell malignancies (such as
Acute Lymphoblastic Leukemia, or ALL), CAR (chi-
meric antigen receptor) and TCR (T cell receptor) cell
therapies have demonstrated encouraging clinical
results. As we begin to look into targeting solid tumors
with TCR and CAR T cells, the hurdle of being able to
select a suitable target and achieving successful cellular
delivery/homing to the site of disease remains. Addi-
tional challenges include the preparation and adminis-
tration of a therapeutic dose involving minimums such
as 1X109 cells per patient. Here we demonstrate the
application of a clinically applicable perfluorocarbon
(PFC) tracer agent that enables the migration and per-
sistence of cellular therapies to be noninvasively imaged
by 19F MRI. Using a general T cell expansion protocol,
we show that adding a cellular label does not alter the
viability, growth curves, or release characteristics of
T cell therapies, and most importantly, that the labeling
process is able to be performed at a large clinical scale
without detriment to the product. By pairing the PFC
signal with conventional proton MRI from the same
imaging session, the images are able to be overlaid,
allowing cells to be traced to their anatomical location.
With nominal exogenous fluorine naturally present in
tissue, labeled cells appear with little background.
Further animal biodistribution studies and clinical
patient scans of labeled cells demonstrate both the
migratory capacity of cells between 2 and 24 hours
post-administration and the sensitivity of this method at
clinically relevant scan times. The MRI tracking capabil-
ities, safety profiles, scalability, and clinical sensitivity of
this method demonstrate the ability of 19F to be used in
additional clinical applications in order to visualize the
spatial fate of cellular therapeutics.
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